在血液系统恶性肿瘤伴 B 细胞耗竭的患者中，早期给予瑞德西韦联合恢复期血浆治疗对 COVID-19 肺炎有效

Patients with hematological malignancies (HMs) are at a higher risk of developing severe form and protracted course of COVID-19 disease.

We investigated whether the combination of viral replication inhibition with remdesivir and administration of anti-SARS-CoV-2 immunoglobulins with convalescent plasma (CP) therapy might be sufficient to treat B-cell-depleted patients with COVID-19.

We enrolled 20 consecutive patients with various HMs with profound B-cell lymphopenia and COVID-19 pneumonia between December 2020 and May 2021. All patients demonstrated undetectable baseline anti-SARS-CoV-2 immunoglobulin levels before CP. Each patient received at least a complete course of remdesivir and at least one unit of CP.

Previous anti-CD20 therapy resulted in a more prolonged SARS-CoV-2 PCR positivity compared to other causes of B-cell lymphopenia (p = 0. 004). Timing of CP therapy showed a significant impact on the clinical outcome. Simultaneous use of remdesivir and CP reduced time period for oxygen weaning after diagnosis (p = 0. 017), length of hospital stay (p = 0. 007), and PCR positivity (p = 0. 012) compared to patients who received remdesivir and CP consecutively.

In addition, time from the diagnosis to CP therapy affected the length of oxygen dependency (p < 0. 001) and hospital stay (p < 0. 0001). In those cases where there were at least 10 days from the diagnosis to plasma administration, oxygen dependency was prolonged vs. patients with shorter interval (p = 0. 006).

In conclusion, the combination of inhibition of viral replication with passive immunization was proved to be efficient and safe.

Our results suggest the clear benefit of early, combined administration of remdesivir and CP to avoid protracted COVID-19 disease among patients with HMs and B-cell lymphopenia.